Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1803 results
November 2017
-
Media ReleaseNovartis highlights its differentiated late stage pipeline at the R&D update and investor eventRTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD AMG 334 has a…
-
Media ReleaseNew Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failureEntresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common…
-
Media ReleasePunjab province in Pakistan signs agreement with Novartis Access against chronic diseasesPoor patients in Punjab will have access to high-quality medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will…
-
Key ReleaseNovartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindnessBrolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-…
-
Conversations with Patient Advocates: Ron Hollander, president of INCA
Ron Hollander, president of the International Neuroendocrine Cancer Alliance, talks to us about patient advocacy.
-
Media ReleaseNovartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancerMONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal…
-
Media ReleaseNovartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damageStructural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced…
-
Media ReleaseNovartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 yearsFor the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx® have no radiographic progression of the spine at 4 years[1] These new data…
-
Media ReleaseNovartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCLApplication follows sBLA submission to the FDA for r/r DLBCL which marked second US application for first-ever FDA approved CAR-T therapy Building on the US r/r B-cell ALL experience, Novartis…
-
Targeting the roots of Sjögren’s syndrome
Early clinical trial reports results in this hidden disease
-
Media ReleaseNovartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention programParties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD) Clinical trial is part of the…
-
Media ReleaseNovartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell diseasePrimary results of pivotal KymriahTM Phase II JULIET study in relapsed/refractory DLBCL Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to…
Pagination
- ‹ Previous page
- 1
- …
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- …
- 151
- › Next page